Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | Overcoming resistance to CAR-T therapy in CLL with ibrutinib & venetoclax

Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, discusses strategies to overcome resistance to CAR-T therapy in chronic lymphocytic leukemia (CLL), commenting on the addition of ibrutinib and venetoclax to CAR-T therapy, and highlighting the use of gene editing techniques to engineer improved CAR-T constructs. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.